Articoli con mandati relativi all'accesso pubblico - sankar navaneethanUlteriori informazioni
Non disponibili pubblicamente: 25
Type 2 diabetes and osteoarthritis: a systematic review and meta-analysis
MF Williams, DA London, EM Husni, S Navaneethan, SR Kashyap
Journal of Diabetes and its Complications 30 (5), 944-950, 2016
Mandati: US National Institutes of Health
Primary and secondary prevention of cardiovascular disease in patients with chronic kidney disease
S Ali, N Dave, SS Virani, SD Navaneethan
Current Atherosclerosis Reports 21, 1-9, 2019
Mandati: US National Institutes of Health
Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease
SD Navaneethan, J Hegbrant, GFM Strippoli
Current Opinion in Nephrology and Hypertension 20 (2), 146-152, 2011
Mandati: US National Institutes of Health
Long-term inter-platform reproducibility, bias, and linearity of commercial PDFF MRI methods for fat quantification: a multi-center, multi-vendor phantom study
E Schneider, EM Remer, NA Obuchowski, CA McKenzie, X Ding, ...
European Radiology 31, 7566-7574, 2021
Mandati: US National Institutes of Health
How to design a randomized controlled trial
SD Navaneethan, SC Palmer, A Smith, DW Johnson, GFM Strippoli
Nephrology 15 (8), 732-739, 2010
Mandati: US National Institutes of Health
Blood pressure parameters and their associations with death in patients with chronic kidney disease
S Qureshi, R Lorch, SD Navaneethan
Current Hypertension Reports 19, 1-7, 2017
Mandati: US National Institutes of Health
Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: insights from the Department of Veterans Affairs
M Al Rifai, D Mahtta, DJ Ramsey, MT Lee, C Krittanawong, ...
American Heart Journal 248, 160-162, 2022
Mandati: US Department of Veterans Affairs
A mistake not to be repeated: what can we learn from the underutilization of statin therapy for efficient dissemination of cardioprotective glucose lowering agents?
NS Maitra, D Mahtta, S Navaneethan, EM Vaughan, A Kochar, M Gulati, ...
Current cardiology reports 24 (6), 689-698, 2022
Mandati: US National Institutes of Health, US Department of Veterans Affairs
Hospitalization and critical illness in chronic kidney disease
JL Triozzi, J Niu, CP Walther, WC Winkelmayer, SD Navaneethan
Cardiorenal Medicine 10 (5), 302-312, 2020
Mandati: US National Institutes of Health
Early eGFR decline after SGLT2i initiation: knowns and unknowns
LP Gregg, SD Navaneethan
Kidney International 99 (3), 548-550, 2021
Mandati: US National Institutes of Health, US Department of Veterans Affairs
Emerging therapeutic options for managing diabetic kidney disease
CP Walther, A Whaley-Connell, SD Navaneethan
Current Opinion in Nephrology and Hypertension 26 (5), 335-337, 2017
Mandati: US Department of Veterans Affairs
Predictors and Outcomes of Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in CKD: SA-PO482
LP Gregg, P Richardson, V Nambi, ME Matheny, SS Virani, ...
Journal of the American Society of Nephrology 34 (11S), 857, 2023
Mandati: US National Institutes of Health, US Department of Veterans Affairs
Kidney Function Trajectories, Risk Factors, and Outcomes in Left Ventricular Assist Device (LVAD) Recipients: FR-OR94
CP Walther, N Mondal, SD Navaneethan
Journal of the American Society of Nephrology 34 (11S), 55-56, 2023
Mandati: US National Institutes of Health
Predictors and Outcomes of Discontinuation of Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2is) in CKD: TH-PO1025
LP Gregg, P Richardson, V Nambi, ME Matheny, SS Virani, ...
Journal of the American Society of Nephrology 34 (11S), 378, 2023
Mandati: US National Institutes of Health, US Department of Veterans Affairs
ACEi/Angiotensin Receptor Blocker (ARB) Prescribing Practices and Patient Experiences in CKD: A Qualitative Study of Clinicians and Patients: TH-PO1026
LP Gregg, J Arney, SR Wydermyer, MA Herrera, P Richardson, ...
Journal of the American Society of Nephrology 34 (11S), 378-379, 2023
Mandati: US Department of Veterans Affairs
Association of Antihypertensive Medications with Cardiovascular (CV) Outcomes in Patients with CKD: SA-PO536
LP Gregg, AR Perkins, H Yang, V Nambi, S Hedayati, SD Navaneethan, ...
Journal of the American Society of Nephrology 34 (11S), 873, 2023
Mandati: US Department of Veterans Affairs
Echocardiographic parameters and cardiovascular disease in Japanese-and US-based CKD cohorts
CP Walther, SD Navaneethan
Kidney International 103 (5), 837-839, 2023
Mandati: US National Institutes of Health, US Department of Veterans Affairs
Adverse Drug Reactions (ADRs) and Underutilization of ACE Inhibitors and ARBs in CKD: TH-PO607
LP Gregg, P Richardson, J Akeroyd, GT Gobbel, J Arney, SA Jafry, ...
Journal of the American Society of Nephrology 33 (11S), 219, 2022
Mandati: US Department of Veterans Affairs
Predictors and Facility-Level Variation in SGLT2i Prescription Among US Veterans: PUB099
LP Gregg, DJ Ramsey, L Chen, J Akeroyd, SS Virani, SD Navaneethan
Journal of the American Society of Nephrology 33 (11S), 912, 2022
Mandati: US National Institutes of Health, US Department of Veterans Affairs
Advancements in the management of kidney disease and electrolyte derangements
MW Holliday Jr, SD Navaneethan
Current Opinion in Nephrology and Hypertension 31 (5), 395-398, 2022
Mandati: US National Institutes of Health, US Department of Veterans Affairs
Le informazioni sulla pubblicazione e sul finanziamento vengono stabilite automaticamente da un software